Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains

References

• Salk JE. A concept of the mechanism of immunity for preventing paralysis in poliomyelitis. Ann. NY Acad. Sci.61(4), 1023–1036; discussion, 1036–1028 (1955).
   PubMedGoogle Scholar
• Salk JE. Vaccination against paralytic poliomyelitis performance and prospects. Am. J. Public Health Nations Health45(5 Pt 1), 575–596 (1955).
   PubMedGoogle Scholar
• Ehrenfeld E, Modlin J, Chumakov K. Future of polio vaccines. Expert Rev. Vaccines8(7), 899–905 (2009).
   PubMed Web of Science ®Google Scholar
• Salk J, van Wezel AL, Stoeckel P et al. Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis. Dev. Biol. Stand.47, 181–198 (1981).
   PubMedGoogle Scholar
• Minor P. Gaps in scientific knowledge for the post eradication world. Biologicals34(2), 167–170 (2006).
   PubMedGoogle Scholar
• Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J. Infect. Dis.151(3), 420–436 (1985).
   PubMed Web of Science ®Google Scholar
• WHO. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper – recommendations. Vaccine28(43), 6943–6944 (2010).
   PubMedGoogle Scholar
• Agol VI. Vaccine-derived polioviruses. Biologicals34(2), 103–108 (2006).
   PubMed Web of Science ®Google Scholar
• Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol.59, 587–635 (2005).
   PubMed Web of Science ®Google Scholar
• Jenkins HE, Aylward RB, Gasasira A et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N. Engl. J. Med.362(25), 2360–2369 (2010).
   PubMed Web of Science ®Google Scholar
• Dragunsky EM, Ivanov AP, Wells VR et al. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy. J. Infect. Dis.190(8), 1404–1412 (2004).
   PubMedGoogle Scholar
• Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine27(20), 2649–2652 (2009).
   PubMed Web of Science ®Google Scholar
• Chumakov K, Ehrenfeld E. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clin. Infect. Dis.47(12), 1587–1592 (2008).
   PubMed Web of Science ®Google Scholar
• Heinsbroek E, Ruitenberg EJ. The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox. Vaccine28(22), 3778–3783 (2010).
   PubMedGoogle Scholar
• Doi Y, Abe S, Yamamoto H et al. Progress with inactivated poliovirus vaccines derived from the Sabin strains. Dev. Biol. (Basel)105, 163–169 (2001).
   PubMedGoogle Scholar
• Simizu B, Abe S, Yamamoto H et al. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals34(2), 151–154 (2006).
   PubMed Web of Science ®Google Scholar
• Aylward BR, Sutter RW, Cochi SL, Thompson KM, Jafari H, Heymann D. Risk management in a polio-free world. Risk Anal.26(6), 1441–1448 (2006).
   PubMed Web of Science ®Google Scholar
• Heymann DL, Sutter RW, Aylward RB. A global call for new polio vaccines. Nature434(7034), 699–700 (2005).
   PubMed Web of Science ®Google Scholar
• Duchene M, Peetermans J, D’Hondt E, Harford N, Fabry L, Stephenne J. Production of poliovirus vaccines: past, present, and future. Viral Immunol.3(4), 243–272 (1990).
   PubMedGoogle Scholar
• Minor PD. The molecular biology of poliovaccines. J. Gen. Virol.73(Pt 12), 3065–3077 (1992).
   PubMedGoogle Scholar
• Tebbens RJ, Pallansch MA, Kew OM et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal.26(6), 1471–1505 (2006).
   PubMed Web of Science ®Google Scholar
• Fine PE, Ritchie S. Perspective: determinants of the severity of poliovirus outbreaks in the post eradication era. Risk Anal.26(6), 1533–1540 (2006).
   PubMed Web of Science ®Google Scholar
• Thomassen YE, van Sprang ENM, van der Pol LA, Bakker WAM. Multivariate data analysis on historical IPV production data for better process understanding and future improvements. Biotechnol. Bioeng.107(1), 96–104 (2010).
   PubMedGoogle Scholar
• Westdijk J, Brugmans D, Martin J et al. Characterization and standardization of sabin based inactivated polio vaccine. Proposal for a new antigen unit for inactivated polio vaccines. Vaccine29(18), 3390–3397 (2011).
   PubMed Web of Science ®Google Scholar
• Bakker WAM, Thomassen YE, van der Pol LA. Scale-down approach for animal-free polio vaccine production. In: Cells and Culture; Proceedings of the 20th ESACT meeting, June 17–20, 2007, Dresden, Germany. Noll T (Ed.). Springer, Berlin, Germany, 541–550 (2010).
   Google Scholar
• Bevilacqua JM, Young L, Chiu SW, Sparkes JD, Kreeftenberg JG. Rat immunogenicity assay of inactivated poliovirus. Dev. Biol. Stand.86, 121–127 (1996).
   PubMedGoogle Scholar
• Tano Y, Shimizu H, Martin J, Nishimura Y, Simizu B, Miyamura T. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine25(41), 7041–7046 (2007).
   PubMed Web of Science ®Google Scholar
• Kersten G, Hazendonk T, Beuvery C. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine17(15–16), 2059–2066 (1999).
   PubMed Web of Science ®Google Scholar
• Dragunsky EM, Ivanov AP, Abe S et al. Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine. J. Infect. Dis.194(6), 804–807 (2006).
   PubMedGoogle Scholar
• Murph JR, Grose C, McAndrew P et al. Sabin inactivated trivalent poliovirus vaccine: first clinical trial and seroimmunity survey. Pediatr. Infect. Dis. J.7(11), 760–765 (1988).
   PubMedGoogle Scholar
• Simizu B. Development of Sabin-inactivated poliovirus vaccine. Presented at: Polio Immunization: Moving Forward. NIH, Bethesda, USA, September 19–20 (2007).
   Google Scholar
• Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO collaborative study group on oral and inactivated poliovirus vaccines. Bull. World Health Organ.74(3), 253–268 (1996).
   PubMed Web of Science ®Google Scholar
• Asturias EJ, Dueger EL, Omer SB et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. J. Infect. Dis.196(5), 692–698 (2007).
   PubMed Web of Science ®Google Scholar
• Cuba IPV Study Collaborative Group. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N. Engl. J. Med.356(15), 1536–1544 (2007).
   PubMed Web of Science ®Google Scholar
• Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. Wkly Epidemiol. Rec.78(28), 241–250 (2003).
   PubMedGoogle Scholar
• Plotkin SA, Vidor E. Chapter 25: Poliovirus vaccine-inactivated. In: Vaccines Expert Consult. Saunders, Philadelphia, PA, USA (2008).
   Google Scholar
• Haastrup E, Thierry-Carstensen B, Jensen AM, Stellfeld M, Heilmann C. Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in Vero-cells. Vaccine22(8), 958–962 (2004).
   PubMedGoogle Scholar
• Rumke H, Labadie J, Elzinga-Gholizadea N, Mensinga T. IPV-Vero vaccine induces a strong booster reaction and is well tolerated in adults. Scand J. Infect. Dis.30(5), 535–538 (1998).
   PubMedGoogle Scholar
• Salk J, Salk D. Control of influenza and poliomyelitis with killed virus vaccines. Science195(4281), 834–847 (1977).
   PubMed Web of Science ®Google Scholar
• Salk J. Immune response and minimum requirement for immunity to disease. Scand. J. Infect. Dis. Suppl.36, 65–67 (1982).
   PubMedGoogle Scholar
• Bottiger M. Polio immunity to killed vaccine: an 18-year follow-up. Vaccine8(5), 443–445 (1990).
   PubMed Web of Science ®Google Scholar
• Conyn-Van Spaendonck MA, de Melker HE, Abbink F, Elzinga-Gholizadea N, Kimman TG, van Loon T. Immunity to poliomyelitis in The Netherlands. Am. J. Epidemiol.153(3), 207–214 (2001).
   PubMedGoogle Scholar
• Grimprel E, von Sonnenburg F, Sanger R, Abitbol V, Wolter JM, Schuerman LM. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine23(28), 3657–3667 (2005).
   PubMed Web of Science ®Google Scholar
• Rumke HC, Oostvogel PM, Van Steenis G, Van Loon AM. Poliomyelitis in The Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992. Epidemiol. Infect.115(2), 289–298 (1995).
   PubMed Web of Science ®Google Scholar
• Martin J, Crossland G, Wood DJ, Minor PD. Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. J. Gen. Virol.84(Pt 7), 1781–1788 (2003).
   PubMed Web of Science ®Google Scholar
• Rezapkin G, Martin J, Chumakov K. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method. Biologicals33(1), 29–39 (2005).
   PubMedGoogle Scholar
• Salk J, Stoeckel P, van Wezel AL, Lapinleimu K, van Steenis G. Antigen content of inactivated poliovirus vaccine for use in a one- or two-dose regimen. Ann. Clin. Res.14(5–6), 204–212 (1982).
   PubMedGoogle Scholar
• Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J. Infect. Dis.162(6), 1291–1297 (1990).
   PubMed Web of Science ®Google Scholar
• McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am. J. Epidemiol.128(3), 615–628 (1988).
   PubMed Web of Science ®Google Scholar
• Nirmal S, Cherian T, Samuel BU, Rajasingh J, Raghupathy P, John TJ. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine16(9–10), 928–931 (1998).
   PubMed Web of Science ®Google Scholar
• Simasathien S, Migasena S, Beuvery C et al. Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants. Scand. J. Infect. Dis.26(6), 731–738 (1994).
   PubMed Web of Science ®Google Scholar
• Krishnan R, Jadhav M, John TJ. Efficacy of inactivated poliovirus vaccine in India. Bull. World Health Organ.61(4), 689–692 (1983).
   PubMed Web of Science ®Google Scholar
• Sormunen H, Stenvik M, Eskola J, Hovi T. Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine. J. Med. Virol.63(4), 305–310 (2001).
   PubMed Web of Science ®Google Scholar
• Taranger J, Trollfors B, Knutsson N, Sundh V, Lagergard T, Ostergaard E. Vaccination of infants with a four-dose and a three-dose vaccination schedule. Vaccine18(9–10), 884–891 (2000).
   Google Scholar
• Perkins FT, Yetts R, Gaisford W. Serological response of infants to poliomyelitis vaccine. Br. Med. J.2(5088), 68–71 (1958).
   PubMedGoogle Scholar
• Simoes EA, Padmini B, Steinhoff MC, Jadhav M, John TJ. Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. Am. J. Dis. Child.139(10), 977–980 (1985).
   PubMedGoogle Scholar
• Dayan GH, Thorley M, Yamamura Y et al. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J. Infect. Dis.195(1), 12–20 (2007).
   PubMed Web of Science ®Google Scholar
• Kok PW, Leeuwenburg J, Tukei P et al. Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya. Bull. World Health Organ.70(1), 93–103 (1992).
   PubMedGoogle Scholar
• Swartz TA, Handsher R, Stoeckel P et al. Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule. Eur. J. Epidemiol.5(2), 143–145 (1989).
   PubMedGoogle Scholar
• Krishnan R, Jadhav M, Selvakumar R, John TJ. Immune response of infants in tropics to injectable polio vaccine. Br. Med. J. (Clin. Res. Ed.)284(6310), 164 (1982).
   PubMedGoogle Scholar
• Simoes EA, John TJ. The antibody response of seronegative infants to inactivated poliovirus vaccine of enhanced potency. J. Biol. Stand.14(2), 127–131 (1986).
   PubMedGoogle Scholar
• Salk J. One-dose immunization against paralytic poliomyelitis using a noninfectious vaccine. Rev. Infect. Dis.6(Suppl. 2), S444–S450 (1984).
   PubMedGoogle Scholar
• Clark TW, Pareek M, Hoschler K et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N. Engl. J. Med.361(25), 2424–2435 (2009).
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Spaczynski M, Schneider A et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years. Vaccine27(4), 581–587 (2009).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Tilman S et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics126(4), e762–e770 (2010).
   PubMed Web of Science ®Google Scholar
• Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol. Oncol.109(Suppl. 2), S15–S21 (2008).
   PubMed Web of Science ®Google Scholar
• Baldwin SL, Fox CB, Pallansch MA, Coler RN, Reed SG, Friede M. Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions. Vaccine29(4), 644–649 (2011).
   PubMed Web of Science ®Google Scholar
• Yang C, Shi H, Zhou J, Liang Y, Xu H. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus. Vaccine27(47), 6558–6563 (2009).
   PubMedGoogle Scholar
• Ivanov AP, Dragunsky EM, Chumakov KM. 1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. J. Infect. Dis.193(4), 598–600 (2006).
   PubMed Web of Science ®Google Scholar
• Salk J, Cohen H, Fillastre C et al. Killed poliovirus antigen titration in humans. Dev. Biol. Stand.41, 119–132 (1978).
   PubMedGoogle Scholar
• Resik S, Tejeda A, Lago PM et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J. Infect. Dis.201(9), 1344–1352 (2010).
   PubMed Web of Science ®Google Scholar
• Mohammed AJ, AlAwaidy S, Bawikar S et al. Fractional doses of inactivated poliovirus vaccine in Oman. N. Engl. J. Med.362(25), 2351–2359 (2010).
   PubMed Web of Science ®Google Scholar
• Burns CC, Campagnoli R, Shaw J, Vincent A, Jorba J, Kew O. Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons. J. Virol.83(19), 9957–9969 (2009).
   PubMedGoogle Scholar
• Cello J, Paul AV, Wimmer E. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science297(5583), 1016–1018 (2002).
   PubMed Web of Science ®Google Scholar
• Macadam AJ, Ferguson G, Stone DM et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J. Virol.80(17), 8653–8663 (2006).
   PubMed Web of Science ®Google Scholar
• Vignuzzi M, Wendt E, Andino R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat. Med.14(2), 154–161 (2008).
   PubMed Web of Science ®Google Scholar
• Collett MS, Neyts J, Modlin JF. A case for developing antiviral drugs against polio. Antiviral Res.79(3), 179–187 (2008).
   PubMed Web of Science ®Google Scholar
• Norder H, De Palma AM, Selisko B et al. Picornavirus non-structural proteins as targets for new anti-virals with broad activity. Antiviral Res.89(3), 204–218 (2011).
   PubMed Web of Science ®Google Scholar